The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats

This publication has 32 references indexed in Scilit:

• The anti-inflammatory effect of A₃adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis
  Expert Opinion on Investigational Drugs, 2007
• Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase‐3β
  British Journal of Pharmacology, 2006
• GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat*
  Critical Care Medicine, 2005
• Diclofenac attenuates Wnt/β‐catenin signaling in colon cancer cells by activation of NF‐κB
  FEBS Letters, 2005
• Crosstalk between NF-κB and β-catenin pathways in bacterial-colonized intestinal epithelial cells
  American Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
• Activation of A3 Adenosine Receptor Provides Lung Protection Against Ischemia-Reperfusion Injury Associated with Reduction in Apoptosis
  American Journal of Transplantation, 2004
• Agonists to the A3 adenosine receptor induce G-CSF production via NF-κB activation
  Experimental Hematology, 2002
• Right Thing at a Wrong Time?. Adenosine A₃ Receptors and Cerebroprotection in Stroke
  Annals of the New York Academy of Sciences, 2001
• Two distinct subpopulations of endosomes involved in membrane recycling and transport to lysosomes
  Cell, 1988
• Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
  Biochemical Pharmacology, 1973